Albert Do, MD, MPH
Assistant Professor Adjunct; Clinical Director, Fatty Liver Disease Program
Research & Publications
Biography
News
Coauthors
Selected Publications
- S1581 Assessing the Effectiveness of Incorporating Weight Management Treatments Into a Fatty Liver Disease ProgramDo A, Ilagan-Ying Y, Deng Y, Banini B, Lim J, Mehal W. S1581 Assessing the Effectiveness of Incorporating Weight Management Treatments Into a Fatty Liver Disease Program. The American Journal Of Gastroenterology 2023, 118: s1193-s1194. DOI: 10.14309/01.ajg.0000955964.73046.7b.
- Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical PracticeIlagan-Ying Y, Banini B, Do A, Lam R, Lim J. Screening, Diagnosis, and Staging of Non-Alcoholic Fatty Liver Disease (NAFLD): Application of Society Guidelines to Clinical Practice. Current Gastroenterology Reports 2023, 25: 213-224. PMID: 37768417, DOI: 10.1007/s11894-023-00883-8.
- Exercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-AnalysisChen G, Banini B, Do A, Gunderson C, Zaman S, Lim J. Exercise Does Not Independently Improve Histological Outcomes in Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Genes 2023, 14: 1811. PMID: 37761951, PMCID: PMC10531443, DOI: 10.3390/genes14091811.
- Sa1547 IS TISSUE THE ISSUE? USE AND UTILITY OF LIVER BIOPSY IN A DEDICATED FATTY LIVER DISEASE CLINIC INCORPORATING METABOLIC HEALTH CAREIlagan-Ying Y, Tseng R, Valido K, Bollinger B, Kelly M, Do A. Sa1547 IS TISSUE THE ISSUE? USE AND UTILITY OF LIVER BIOPSY IN A DEDICATED FATTY LIVER DISEASE CLINIC INCORPORATING METABOLIC HEALTH CARE. Gastroenterology 2023, 164: s-1286-s-1287. DOI: 10.1016/s0016-5085(23)03992-6.
- Broadening Horizons: Why Gastroenterologists Should Consider a Career in Obesity MedicineDo A, Xu J. Broadening Horizons: Why Gastroenterologists Should Consider a Career in Obesity Medicine. Digestive Diseases And Sciences 2023, 68: 725-728. PMID: 36670325, DOI: 10.1007/s10620-023-07827-2.
- The Independent Effect of Exercise on Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic ReviewChen G, Banini B, Do A, Lim J. The Independent Effect of Exercise on Biopsy-Proven Non-Alcoholic Fatty Liver Disease: A Systematic Review. Clinical And Molecular Hepatology 2022, 29: s319-s332. PMID: 36517000, PMCID: PMC10029942, DOI: 10.3350/cmh.2022.0366.
- S1358 Nonalcoholic Fatty Liver Disease Outcomes in Patients With Comorbid Psychiatric Disorders Improved by Integrated Medical Weight Management and Hepatology Clinic CareIlagan-Ying Y, Cotter R, Bollinger B, Mehal W, Do A. S1358 Nonalcoholic Fatty Liver Disease Outcomes in Patients With Comorbid Psychiatric Disorders Improved by Integrated Medical Weight Management and Hepatology Clinic Care. The American Journal Of Gastroenterology 2022, 117: e975-e976. DOI: 10.14309/01.ajg.0000862072.84358.84.
- S1345 Weight Loss Outcomes With and Without Diabetes in Patients With NAFLD in a Specialty Fatty Liver Disease ProgramIlagan-Ying Y, Valido K, Chehayeb R, Bollinger B, Mehal W, Do A. S1345 Weight Loss Outcomes With and Without Diabetes in Patients With NAFLD in a Specialty Fatty Liver Disease Program. The American Journal Of Gastroenterology 2022, 117: e967-e968. DOI: 10.14309/01.ajg.0000862020.76034.41.
- S1453 Weight Loss in Bariatric Surgery Patients Treated at a Novel Clinic Incorporating Obesity Medicine for Treatment of Nonalcoholic Fatty Liver DiseaseIlagan-Ying Y, Schwartz A, Park E, Bollinger B, Ying L, Mehal W, Do A. S1453 Weight Loss in Bariatric Surgery Patients Treated at a Novel Clinic Incorporating Obesity Medicine for Treatment of Nonalcoholic Fatty Liver Disease. The American Journal Of Gastroenterology 2022, 117: e1043-e1044. DOI: 10.14309/01.ajg.0000862452.53915.0f.
- Clinical Phenotyping and the Application of Precision Medicine in MAFLDSaffo S, Do A. Clinical Phenotyping and the Application of Precision Medicine in MAFLD. Clinical Liver Disease 2022, 19: 227-233. PMID: 35795621, PMCID: PMC9248929, DOI: 10.1002/cld.1199.
- Increased Mortality in Patients Undergoing Inpatient Endoscopy During the Early COVID-19 PandemicIlagan-Ying YC, Almeida MN, Kahler-Quesada A, Ying L, Hughes ML, Do A, Hung KW. Increased Mortality in Patients Undergoing Inpatient Endoscopy During the Early COVID-19 Pandemic. Digestive Diseases And Sciences 2022, 67: 5053-5062. PMID: 35182250, PMCID: PMC8857390, DOI: 10.1007/s10620-022-07414-x.
- S1125 The Impact of Dietary Composition on Non-Alcoholic Fatty Liver Disease and Advanced Fibrosis in U.S. AdultsOchoa-Allemant P, Ilagan-Ying Y, Do A. S1125 The Impact of Dietary Composition on Non-Alcoholic Fatty Liver Disease and Advanced Fibrosis in U.S. Adults. The American Journal Of Gastroenterology 2021, 116: s529-s529. DOI: 10.14309/01.ajg.0000778032.99095.98.
- Sa623 PROVIDER KNOWLEDGE, ATTITUTDES, AND PRACTICES FOR OBESITY MANAGEMENT AMONG MEDICATION PRESCRIBERS COMPARED TO NON-PRESCRIBERSIlagan-Ying Y, Almeida M, Ying L, Viana A, Yang Y, Do A. Sa623 PROVIDER KNOWLEDGE, ATTITUTDES, AND PRACTICES FOR OBESITY MANAGEMENT AMONG MEDICATION PRESCRIBERS COMPARED TO NON-PRESCRIBERS. Gastroenterology 2021, 160: s-578-s-579. DOI: 10.1016/s0016-5085(21)02079-5.
- 921 WEIGHING THE OPTIONS: ATTITUDES AND PERCEPTIONS OF BARIATRIC SURGERY AMONGST PROVIDERS BASED ON REFERRAL PATTERNSYing L, Ilagan-Ying Y, Almeida M, Viana A, Yang Y, Morton J, Do A. 921 WEIGHING THE OPTIONS: ATTITUDES AND PERCEPTIONS OF BARIATRIC SURGERY AMONGST PROVIDERS BASED ON REFERRAL PATTERNS. Gastroenterology 2021, 160: s-910. DOI: 10.1016/s0016-5085(21)02912-7.
- Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpointsDo A, Ilagan-Ying YC, Mehal WZ, Lim JK. Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints. Expert Opinion On Drug Discovery 2020, 16: 125-134. PMID: 33086894, DOI: 10.1080/17460441.2020.1811674.
- Correction to: Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting AntiviralsDo A, Esserman DA, Krishnan S, Lim JK, Taddei TH, Hauser RG, Tate JP, Re VL, Justice AC. Correction to: Excess Weight Gain After Cure of Hepatitis C Infection with Direct-Acting Antivirals. Journal Of General Internal Medicine 2020, 35: 3140-3140. PMID: 33021712, PMCID: PMC7572953, DOI: 10.1007/s11606-020-06227-w.
- S0564 Understanding the Impact of the COVID-19 Pandemic on Inpatient Gastrointestinal Procedures: A Single Center StudyIlagan-Ying Y, Almeida M, Kahler-Quesada A, Ying L, Do A, Hughes M, Hung K. S0564 Understanding the Impact of the COVID-19 Pandemic on Inpatient Gastrointestinal Procedures: A Single Center Study. The American Journal Of Gastroenterology 2020, 115: s259-s259. DOI: 10.14309/01.ajg.0000704304.38893.a6.
- S1015 Bariatric Surgery Can Be Performed Safely at Yale-New Haven Hospital in Patients With CirrhosisMankash M, Yousaf M, Duffy A, Mehal W, Do A. S1015 Bariatric Surgery Can Be Performed Safely at Yale-New Haven Hospital in Patients With Cirrhosis. The American Journal Of Gastroenterology 2020, 115: s518-s518. DOI: 10.14309/01.ajg.0000706108.48385.f8.
- S1016 Tolerance and Safety of Meal Replacement Program in Nonalcoholic Steatohepatitis With Fibrosis and Cirrhosis: A Case SeriesMankash M, Kelly M, Mehal W, Do A. S1016 Tolerance and Safety of Meal Replacement Program in Nonalcoholic Steatohepatitis With Fibrosis and Cirrhosis: A Case Series. The American Journal Of Gastroenterology 2020, 115: s518-s519. DOI: 10.14309/01.ajg.0000706112.69854.c1.
- S1189 Incorporation of Obesity Medicine Into the Care of Patients With Nonalcoholic Fatty Liver Disease: 1-Year Interim ResultsMankash M, Kelly M, Duffy A, Mehal W, Do A. S1189 Incorporation of Obesity Medicine Into the Care of Patients With Nonalcoholic Fatty Liver Disease: 1-Year Interim Results. The American Journal Of Gastroenterology 2020, 115: s595-s595. DOI: 10.14309/01.ajg.0000706804.10023.a3.
- Collaborative leadership: organisational structure and institutional investment to multiply innovative educational efforts among traineesDo A, Li L, Heller D, Ziki M, Glaser D, Kumar S, Huot S. Collaborative leadership: organisational structure and institutional investment to multiply innovative educational efforts among trainees. BMJ Leader 2020, 5: 55-58. DOI: 10.1136/leader-2020-000233.
- Medical Approach for Weight Loss in Nonalcoholic Fatty Liver DiseaseDo A, Ilagan-Ying Y, Mehal W. Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports 2019, 18: 444-454. DOI: 10.1007/s11901-019-00498-6.
- 1056 Incorporation of Obesity Management into the Care of Patients With Nonalcoholic Steatohepatitis: The Yale Fatty Liver Disease ModelMankash M, Kelly M, Dean J, Duffy A, Mehal W, Do A. 1056 Incorporation of Obesity Management into the Care of Patients With Nonalcoholic Steatohepatitis: The Yale Fatty Liver Disease Model. The American Journal Of Gastroenterology 2019, 114: s599-s599. DOI: 10.14309/01.ajg.0000593756.22484.ae.
- Outcomes Associated With Percutaneous Coronary Intervention in Patients With NASH Cirrhosis: Analysis of the National Inpatient Sample 2004-2014Ilagan-Ying Y, Kim Y, Do A. Outcomes Associated With Percutaneous Coronary Intervention in Patients With NASH Cirrhosis: Analysis of the National Inpatient Sample 2004-2014. The American Journal Of Gastroenterology 2018, 113: s562. DOI: 10.14309/00000434-201810001-01004.
- Sa1443 - Effect of Weekend Admission for Acute Liver Failure: Analysis of the National Inpatient SampleDo A, Taddei T, Ilagan-Ying Y. Sa1443 - Effect of Weekend Admission for Acute Liver Failure: Analysis of the National Inpatient Sample. Gastroenterology 2018, 154: s-1115. DOI: 10.1016/s0016-5085(18)33710-7.
- Vitamin D and Colorectal CancerDo A, Protiva P. Vitamin D and Colorectal Cancer. 2018, 103-114. DOI: 10.1007/978-3-319-73742-3_5.
- Mo1383 Weight Change After Receipt of Direct-Acting Antiviral Agents for Hepatitis CDo A, Esserman D, Tate J, Njei B, Levin F, Lim J, Taddei T, Justice A. Mo1383 Weight Change After Receipt of Direct-Acting Antiviral Agents for Hepatitis C. Gastroenterology 2017, 152: s1163. DOI: 10.1016/s0016-5085(17)33893-3.
- A New Clinical Paradigm for Hepatitis C End-Stage Renal Disease Patients: Balancing Viral Eradication and Early Kidney TransplantationKulkarni S, Do A, Liapakis A. A New Clinical Paradigm for Hepatitis C End-Stage Renal Disease Patients: Balancing Viral Eradication and Early Kidney Transplantation. Internal Medicine Review 2017, 3 DOI: 10.18103/imr.v3i9.570.
- Tu1683 Epidemiological Trends in Acute, Carrier, and Chronic Hepatitis B Infection in Hospitalized Patients: A Study of the Nationwide Inpatient Sample, 2000 to 2012Do A, Njei B, Lim J. Tu1683 Epidemiological Trends in Acute, Carrier, and Chronic Hepatitis B Infection in Hospitalized Patients: A Study of the Nationwide Inpatient Sample, 2000 to 2012. Gastroenterology 2016, 150: s924. DOI: 10.1016/s0016-5085(16)33132-8.
- Mo1467 Acute Liver Failure Precipitated by Budd-Chiari Syndrome Associated with JAK-2-Positive Polycythemia Vera and Gallbladder AdenocarcinomaDo A, Hung A, Pelland K, Cho M, Mitchell-Richards K, Jakab S. Mo1467 Acute Liver Failure Precipitated by Budd-Chiari Syndrome Associated with JAK-2-Positive Polycythemia Vera and Gallbladder Adenocarcinoma. Gastroenterology 2016, 150: s1123. DOI: 10.1016/s0016-5085(16)33790-8.
- 600a National Trends in Utilization, Mortality, and Cost of Care for Chronic Hepatitis B Virus Infection 2000-2012: Analysis of the Nationwide Inpatient Sample (NIS)Do A, Luk J, Njei B, Lim J. 600a National Trends in Utilization, Mortality, and Cost of Care for Chronic Hepatitis B Virus Infection 2000-2012: Analysis of the Nationwide Inpatient Sample (NIS). Gastroenterology 2016, 150: s123. DOI: 10.1016/s0016-5085(16)30518-2.
- Tu1044 Sofosbuvir-Based Interferon-Free Regimens for Hepatitis C Infection in Patients With Compensated and Decompensated Cirrhosis: Interim Analysis of a Prospective Observational CohortDo A, Lim J, Liapakis A, Babas G, Caldwell C, Fortune B, Emre S, Kulkarni S, Lempit S, Mistry P, Mulligan D, Rodriguez-Davalos M, Schilsky M, Tichy E, Yoo P, Jakab S. Tu1044 Sofosbuvir-Based Interferon-Free Regimens for Hepatitis C Infection in Patients With Compensated and Decompensated Cirrhosis: Interim Analysis of a Prospective Observational Cohort. Gastroenterology 2015, 148: s-1094-s-1095. DOI: 10.1016/s0016-5085(15)33733-1.
Clinical Trials
| Conditions | Study Title |
|---|---|
| Diseases of the Digestive System - Liver | Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA) |
| Diseases of the Digestive System - Liver | A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH (VOYAGE) |